Nothing Special   »   [go: up one dir, main page]

ATE73815T1 - Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten. - Google Patents

Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.

Info

Publication number
ATE73815T1
ATE73815T1 AT87810687T AT87810687T ATE73815T1 AT E73815 T1 ATE73815 T1 AT E73815T1 AT 87810687 T AT87810687 T AT 87810687T AT 87810687 T AT87810687 T AT 87810687T AT E73815 T1 ATE73815 T1 AT E73815T1
Authority
AT
Austria
Prior art keywords
active ingredient
pharmaceutical compositions
compositions containing
hydrogen
lower alkyl
Prior art date
Application number
AT87810687T
Other languages
English (en)
Inventor
Toshio Yamada
Ken-Ichi Kageyama
Original Assignee
Nippon Zoki Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co filed Critical Nippon Zoki Pharmaceutical Co
Application granted granted Critical
Publication of ATE73815T1 publication Critical patent/ATE73815T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT87810687T 1986-11-27 1987-11-23 Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten. ATE73815T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP28390486 1986-11-27
EP87810687A EP0269574B1 (de) 1986-11-27 1987-11-23 Adenosin-Derivate und pharmazeutische Zusammenstellungen, welche diese als aktiven Bestandteil enthalten

Publications (1)

Publication Number Publication Date
ATE73815T1 true ATE73815T1 (de) 1992-04-15

Family

ID=17671689

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87810687T ATE73815T1 (de) 1986-11-27 1987-11-23 Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.

Country Status (5)

Country Link
US (1) US4843066A (de)
EP (1) EP0269574B1 (de)
JP (1) JPH0723394B2 (de)
AT (1) ATE73815T1 (de)
DE (1) DE3777554D1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284834A (en) * 1985-03-29 1994-02-08 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Adenosine functionalized congeners as cardiovascular treating agents for animals and methods for using same
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
US5324831A (en) * 1988-04-06 1994-06-28 The United States Of America As Represented By The Secretary Of Health And Human Services Phosphoramidite reagent for chemical synthesis of modified DNA
AU3820989A (en) * 1988-08-02 1990-02-08 Ciba-Geigy Ag 7-amino-3-beta-d-ribofuranosyl-3h-imidazo(4,5-b) pyridin-5-amine derivatives
US4977144A (en) * 1988-08-02 1990-12-11 Ciba-Geigy Corporation Imidazo[4,5-b]pyridine derivatives as cardiovascular agents
US5292725A (en) * 1988-08-25 1994-03-08 Prendergast Patrick T Administering particular compounds against various parasites, mycoplasmas, other indications and other infections
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
JPH0725785B2 (ja) * 1989-01-11 1995-03-22 日本臓器製薬株式会社 アデノシン誘導体及び該化合物を有効成分として含有する医薬組成物
EP0497875B1 (de) 1989-10-24 2000-03-22 Isis Pharmaceuticals, Inc. 2'-modifizierte nukleotide
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5955589A (en) * 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
US5872232A (en) * 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US5859221A (en) * 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5646265A (en) * 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
DE4037363A1 (de) * 1990-04-09 1991-10-10 Europ Lab Molekularbiolog 2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten
US5792844A (en) * 1990-07-27 1998-08-11 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent nitrogen atoms
US5677437A (en) * 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) * 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5386023A (en) * 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
SG80526A1 (en) * 1990-09-25 2001-05-22 Rhone Poulenc Rorer Int Compounds having antihypertensive and anti- ischemic properies
HUT61567A (en) 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US6235887B1 (en) 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5633360A (en) * 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5705491A (en) * 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
US5596094A (en) * 1994-05-26 1997-01-21 Sandoz Ltd. Process for preparing 2' -0- alkyl adenosine derivatives
EP0704215A3 (de) * 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Hemmer der Erhöhung vaskulärer Permeabilität
WO1996003134A1 (en) * 1994-07-21 1996-02-08 Thomas Jefferson University Treatment of diarrhea with 2-substituted adenosine derivatives
US7348315B2 (en) 1995-03-23 2008-03-25 The University Of Connecticut Methods of treating heart failure with modified ATP, ADP and AMP compounds
US5712258A (en) * 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
FR2759091B1 (fr) * 1997-02-06 1999-03-19 Expertises Ind Et Procede biologique d'obtention de nouveaux derives de l'adenosine et les compositions pharmaceutiques qui les contiennent
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6252061B1 (en) 1998-03-23 2001-06-26 Reliable Biopharmaceutical, Inc. Process for the production of 2-halo-6-aminopurine derivatives
JP3619017B2 (ja) 1998-06-24 2005-02-09 日本臓器製薬株式会社 新規アラビノシルアデニン誘導体
AU2002359732A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
WO2004044133A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20080070860A1 (en) * 2005-02-04 2008-03-20 Uti Limited Partnership Adenosine Analogs Useful as Anti-Bacterial and Anti Protozoan Agents
CN100355769C (zh) * 2005-11-16 2007-12-19 华东师范大学 2＇－甲氧基腺苷的制备方法
AU2007263727A1 (en) * 2006-06-27 2008-01-03 Biovitrum Ab (Publ) 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor
EP3212201B1 (de) 2014-10-28 2022-10-19 BCI Pharma Nukleosidkinaseinhibitoren
WO2017137528A1 (en) 2016-02-12 2017-08-17 Charité - Universitätsmedizin Berlin Adenosine a1 receptor agonist for use in treatment of status epilepticus
CA3149846A1 (en) 2019-08-08 2021-02-11 B.C.I. Pharma Quinoline derivatives as protein kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1324011A (fr) * 1962-05-24 1963-04-12 Hoechst Ag Procédé de préparation de nucléosides
NL128576C (de) * 1963-10-07
NL130136C (de) * 1966-10-20
DE1670265A1 (de) * 1967-08-25 1971-01-28 Boehringer Mannheim Gmbh 2-Amino-Adenosinderivate und Verfahren zu deren Herstellung
US3706728A (en) * 1969-03-19 1972-12-19 Boehringer Mannheim Gmbh N(6)-branched chain lower-alkyl-adenosine derivatives
JPS4826038B1 (de) * 1970-09-25 1973-08-03
JPS5630356B2 (de) * 1974-03-12 1981-07-14
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
JPH0696534B2 (ja) * 1986-04-25 1994-11-30 ヘキストジヤパン株式会社 抗痴呆剤

Also Published As

Publication number Publication date
EP0269574A3 (en) 1989-03-22
JPH0723394B2 (ja) 1995-03-15
US4843066A (en) 1989-06-27
EP0269574A2 (de) 1988-06-01
DE3777554D1 (de) 1992-04-23
JPS63239294A (ja) 1988-10-05
EP0269574B1 (de) 1992-03-18

Similar Documents

Publication Publication Date Title
ATE73815T1 (de) Adenosin-derivate und pharmazeutische zusammenstellungen, welche diese als aktiven bestandteil enthalten.
ATE247654T1 (de) Neue heterozyklische verbindungen
ATE79376T1 (de) Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2044836T3 (es) Derivado de la piperidina, su utilizacion y compuesto farmaceutico que lo contiene.
PT100905A (pt) Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
NO163956C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive (4-piperidinylmetyl- og -hetero)puriner.
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
EA199800752A1 (ru) Пентафторбензолсульфонамиды и их аналоги
ATE226574T1 (de) 4,6-diarylpyrimidin-derivate und deren salze
KR880013937A (ko) 옥세타노신 유도체
KR890011902A (ko) 디데옥시디데히드로카르보시클릭 뉴클레오시드
DE68906609D1 (de) Dopamin-vorlaeufer.
ATE48001T1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate.
ATE147625T1 (de) Hydantoin- oder imidazolidintrionderivate zur vorbeugung oder behandlung von niereninsuffizienz
FI834800A (fi) Foerfarande foer framstaellning av dialkylaminoalkoxibensylalkohol-derivat.
EA199800527A1 (ru) Производнфе 2-амино-5,6-дихлорбензимидазола, обладающие противовирусной активностью
ES2077354T3 (es) Derivados de 2-hidroxi-2-feniletilamina utiles como agonistas de beta-3-adrenoceptores.
ATE13423T1 (de) Guanidinderivate und diese enthaltende pharmazeutische zusammensetzungen.
KR950701329A (ko) 벤조티아졸술폰아미드 유도체, 그의 제조법 및 그 용도(Benzothiazolesulfornamide derivative, method for preparing the same, and use thereof)
NO180269C (no) Analogifremgangsmåte for fremstilling av terapeutisk akive aminoketonderivater
NO20022456L (no) Pyrazolo[1,5-d][1,2,4]triazinerderivater for forbedring av kognisjon
DK0420224T3 (da) Anthihepatopatisk middel
DK0570850T3 (da) Benzo(b)thiophen-3-yl-piperaziner, en fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
NO164474C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heksahydropyrrolo(2,1-a)isokinolin-derivater.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties